Decision Analysis and Portfolio Management in the Biopharma Industry

Biopharmaceutical research and development is at a crossroads. Rising development costs, persistent clinical failure, increasing competitive pressures, growing regulatory complexity, and uncertain commercial returns have made “doing more with less” an inherently flawed strategy for achieving success and sustainability.This unique book reframes the conversation, asserting that the true goal is not simply to create value, but to maximize it in the face of risk and uncertainty. By integrating decision analysis with enterprise portfolio management, the book provides leaders with the intellectual and practical foundation needed to make sound, sensitive investment decisions at various stages of drug discovery, clinical development, regulatory approval, and commercialization.Drawing on decades of practical experience, the book builds on CREOPM, first introduced in 2012, as a practical, maturity-sensitive framework designed to embed analytical rigor, strategic clarity, and disciplined governance into the fabric of R&D organizations.This approach goes beyond weak data collection that results in single-point estimates and deterministic scorecards, showing how probabilistic modeling, optimization reasoning, and integrated valuation can transform portfolio construction from reactive budgeting to systematic value optimization. The result is a comprehensive roadmap for organizations seeking to achieve sustainable competitiveness, transparency in decision making, and measurable performance improvement in complex biopharmaceutical industry environments.